RS 102895 manufacturers
- RS 102895
-
-
2026-07-02
- CAS:300815-41-2
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 1000kgs
- RS102895
-
- $59.00
-
2026-06-02
- CAS:300815-41-2
- Purity: 99.80%
- Supply Ability: 10g
- RS 102895
-
-
2025-04-04
- CAS:300815-41-2
- Min. Order: 1kg
- Purity: 98%
- Supply Ability: 1Ton
|
| | RS 102895 Basic information |
| Product Name: | RS 102895 | | Synonyms: | 1'-(4-(TrifluoroMethyl)phenethyl)spiro[benzo[d][1,3]oxazine-4,4'-piperidin]-2(1H)-one hydrochloride;1'-[2-[4-(trifluoromethyl)phenyl]ethyl]spiro[1H-3,1-benzoxazine-4,4'-piperidine]-2-one,hydrochloride;1'-[2-[4-(trifluoromethyl)phenyl]ethyl]-spiro[4h-3,1-benzoxazine-4,4'-peperidin]-2(1h)-one;1'-[2-[4-(TRIFLUOROMETHYL)PHENYL]ETHYL]-SPIRO[4H-3,1-BENZOXAZINE-4,4'-PIPERIDIN]-2(1H)-ONE HYDROCHLORIDE;Spiro[4H-3,1-benzoxazine-4,4'-piperidin]-2(1H)-one, 1'-[2-[4-(trifluoromethyl)phenyl]ethyl]-;1'-(4-(trifluoromethyl)phenethyl)spiro[benzo[d][1,3]oxazine-4,4'-piperidin]-2(1H)-one;CC chemokine receptor,CCR,Inhibitor,RS102895,inhibit,RS-102895,RS 102895;RS102895, 10 mM in DMSO | | CAS: | 300815-41-2 | | MF: | C21H21F3N2O2 | | MW: | 390.4 | | EINECS: | | | Product Categories: | RS 102895 CCR2-selective chemokine receptor antagonist.;Cytokine signaling | | Mol File: | 300815-41-2.mol |  |
| | RS 102895 Chemical Properties |
| Boiling point | 446.1±45.0 °C(Predicted) | | density | 1.33±0.1 g/cm3 (20 ºC 760 Torr) | | storage temp. | Desiccate at RT | | solubility | DMSO: 18 mg/mL, clear, colorless | | form | powder | | pka | 13.46±0.20(Predicted) | | color | white | | InChI | 1S/C21H21F3N2O2.ClH/c22-21(23,24)16-7-5-15(6-8-16)9-12-26-13-10-20(11-14-26)17-3-1-2-4-18(17)25-19(27)28-20;/h1-8H,9-14H2,(H,25,27);1H | | InChIKey | KRRISOFSWVKYBF-UHFFFAOYSA-N | | SMILES | Cl.FC(F)(F)c1ccc(CCN2CCC3(CC2)OC(=O)Nc4ccccc34)cc1 |
| Safety Statements | 22-24/25 | | WGK Germany | 3 | | Storage Class | 11 - Combustible Solids |
| | RS 102895 Usage And Synthesis |
| Uses | RS 102895 is a CCR2-selective chemokine receptor inhibitor. | | Biological Activity | CCR2-selective chemokine receptor antagonist (IC 50 values are 0.36 and 17.8 μ M for inhibition of human recombinant CCR2b and CCR1 receptors respectively). Blocks MCP-1-stimulated calcium influx and chemotaxis with IC 50 values of 32 nM and 1.7 μ M respectively. Also inhibits α 1A , α 1D and 5-HT 1A receptors. | | in vivo | RS102895 (3 g/L) causes progressive decrease in pain threshold in rats with bone cancer pain (BCP) at day 3-9 after surgery via intrathecal injection, but the pain threshold increases after 12 days. RS102895 also potently reverses the pattern of NR2B, nNOS, and SIGIRR expression in spinal cord[3]. | | IC 50 | CCR2: 360 nM (IC50); CCR1: 17800 nM (IC50); Human α1a receptor: 130 nM (IC50); Human α1d receptor: 320 nM (IC50); 5HT-1a receptor: 470 nM (IC50) |
| | RS 102895 Preparation Products And Raw materials |
|